Foley & Lardner LLP represented Amsterdam’s Acrobator Ventures as one of the lead investors in the latest funding round for Latvian-based health-tech company MiLaboratories Inc. Acrobator was joined by Vienna-based Speedinvest III EuVECA GmbH & CoKG as a lead investor in this round.
MiLaboratories is the maker of a software product called MiXCR, a software suite that analyzes genomics data to build a complete picture of the immune response at the DNA level. The MiXCR software and platform, which is AI-driven, has been used in the discovery of Covid-19 vaccines and in helping to treat cancer, antibodies and autoimmune diseases. The capital will be used to continue the development of the MiXCR and next-generation software suite.
Since 2009, the MiLaboratories team has published a series of academic papers on adaptive immunity. Looking to further their research, the team built an R&D algorithm that would lay the groundwork for MiXCR. Today, an augmentation of that original idea includes AI and cloud calculation features used to analyze and process massive genomic data sets, delivering them in a visually friendly format, all at industry-leading speed.
The Foley team was led by Partner Louis Lehot and Associate Alexander Ravski.
Foley’s Venture and Growth Capital Group understands the complex and diverse needs of both venture funds and their portfolio companies, offering a broad range of services at each stage of development. Foley’s attorneys have insight into the unique needs of high-growth companies.
Foley’s Telemedicine & Digital Health Team helps organizations and entrepreneurs embrace emerging issues in healthcare, enabling them to provide innovative care for patients in new markets around the block and around the world. The firm is committed to helping clients fulfill their goals of harnessing new technology to reach patients anywhere and deliver care without borders or geographic limitations. Foley helps clients create fully-fledged offerings, delivering end-to-end legal services by coupling precise strategic guidance with rapid turnarounds to maintain that sense of urgency necessary to launch new initiatives and remain competitive in the marketplace.